中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
Chinese Journal of Experimental Surgery
2015年
9期
2237-2239
,共3页
艾宁%李智岗%冀宏%李顺宗%王永中%李博
艾寧%李智崗%冀宏%李順宗%王永中%李博
애저%리지강%기굉%리순종%왕영중%리박
高尔基体糖蛋白73%甲胎蛋白%原发性肝癌%介入治疗
高爾基體糖蛋白73%甲胎蛋白%原髮性肝癌%介入治療
고이기체당단백73%갑태단백%원발성간암%개입치료
Golgi glycoprotein 73%Alpha-fetoprotein%Primary liver carcinoma%Transcatheter arterial chemoembolization
目的 观察原发性肝癌患者肝动脉灌注化疗栓塞术(TACE)治疗前后血清高尔基体糖蛋白73(GP73)动态表达及联合甲胎蛋白(AFP)检测的临床意义.方法 酶联免疫吸附试验法(ELISA)检测29例正常人以及68例肝癌患者血清GP73水平,并比较患者介入治疗前2d、介入治疗后7d及30 d的血清GP73水平.结果 68例肝癌患者和29例正常对照组GP73水平分别为152.5(76.4 ～284.5)、49.3(12.6～26.7) μg/L,两者比较差异有统计学意义(P＜0.01).血清GP73水平与肝癌患者临床分期明显相关;原发性肝癌患者巴塞罗那临床肝癌分期(BCLC)A、B、C期水平分别为92.12(38.9 ～135.2)、122.90(55.2 ～ 178.5)、162.55(110.8 ～232.9) μg/L,两两比较差异有统计学意义(P＜0.05);介入治疗后7d肝癌患者血清GP73水平为99.2(66.7 ～150.8)明显低于介入治疗前,差异有统计学意义(P＜0.05).AFP＜400 μg/L组中,有49例(75.3％)患者的GP73≥132 μg/L.结论 GP73联合AFP检测有助于肝癌介入疗效的评估及预后预测.
目的 觀察原髮性肝癌患者肝動脈灌註化療栓塞術(TACE)治療前後血清高爾基體糖蛋白73(GP73)動態錶達及聯閤甲胎蛋白(AFP)檢測的臨床意義.方法 酶聯免疫吸附試驗法(ELISA)檢測29例正常人以及68例肝癌患者血清GP73水平,併比較患者介入治療前2d、介入治療後7d及30 d的血清GP73水平.結果 68例肝癌患者和29例正常對照組GP73水平分彆為152.5(76.4 ～284.5)、49.3(12.6～26.7) μg/L,兩者比較差異有統計學意義(P＜0.01).血清GP73水平與肝癌患者臨床分期明顯相關;原髮性肝癌患者巴塞囉那臨床肝癌分期(BCLC)A、B、C期水平分彆為92.12(38.9 ～135.2)、122.90(55.2 ～ 178.5)、162.55(110.8 ～232.9) μg/L,兩兩比較差異有統計學意義(P＜0.05);介入治療後7d肝癌患者血清GP73水平為99.2(66.7 ～150.8)明顯低于介入治療前,差異有統計學意義(P＜0.05).AFP＜400 μg/L組中,有49例(75.3％)患者的GP73≥132 μg/L.結論 GP73聯閤AFP檢測有助于肝癌介入療效的評估及預後預測.
목적 관찰원발성간암환자간동맥관주화료전새술(TACE)치료전후혈청고이기체당단백73(GP73)동태표체급연합갑태단백(AFP)검측적림상의의.방법 매련면역흡부시험법(ELISA)검측29례정상인이급68례간암환자혈청GP73수평,병비교환자개입치료전2d、개입치료후7d급30 d적혈청GP73수평.결과 68례간암환자화29례정상대조조GP73수평분별위152.5(76.4 ～284.5)、49.3(12.6～26.7) μg/L,량자비교차이유통계학의의(P＜0.01).혈청GP73수평여간암환자림상분기명현상관;원발성간암환자파새라나림상간암분기(BCLC)A、B、C기수평분별위92.12(38.9 ～135.2)、122.90(55.2 ～ 178.5)、162.55(110.8 ～232.9) μg/L,량량비교차이유통계학의의(P＜0.05);개입치료후7d간암환자혈청GP73수평위99.2(66.7 ～150.8)명현저우개입치료전,차이유통계학의의(P＜0.05).AFP＜400 μg/L조중,유49례(75.3％)환자적GP73≥132 μg/L.결론 GP73연합AFP검측유조우간암개입료효적평고급예후예측.
Objective To observe the clinical significance of serum golgi glycoprotein 73 (GP73) and alpha-fetoprotein (AFP) test in patients of primary liver carcinoma with transcatheter arterial chemoembolization (TACE) and dynamic changes of GP73.Methods Enzyme-linked immunosorbent assay (ELISA) method was applied to detect 29 cases of normal control people and 68 cases of patients with primary liver carcinoma.The level of serum GP73 were tested on 2 days before the intervention,7 days and 30 days after TACE.Results Serum GP73 level in 68 cases of patients with primary liver carcinoma were higher than 29 normal controls [152.5 (76.4-284.5) vs.49.3 (12.6-26.7) μg/L],and the difference was statistically significant (P ＜0.01).The highly level of serum GP73 was strongly associated with tumor differentiation.The levels of the Barcelona Clinic Liver Cancer (BCLC) A,B,C were 92.12 (38.9-135.2),122.90 (55.2-178.5),162.55 (110.8-232.9) μg/L (P＜0.05).The serum GP73 level at 7 days after TACE [99.2(66.7-150.8)] was significantly lower than before TACE,and the difference was statistically significant (P ＜ 0.05).On the group of patients whose serum AFP showed less than 400 μg/L,serum GP73 of 49 patients (75.3％) showed more than 132 μg/L.Conclusion The test of GP73 and AFP can help to assess the efficacy of TACE and improve the prognosis.
